All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
At the 24th Congress of the European Hematology Association (EHA), Catherine Thieblemont from the Hôpital Saint-Louis, Paris, FR, reports on the first French patients treated with CAR T.
These patients were treated on a compassionate programme and all had relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Having enrolled 60 patients in 5 centers, 53 were treated due to early progression in 7 patients.
Professor Thieblemont notes the very promising results of these patients in relation to progression-free survival and an overall survival rate at 3 months of 80%.
Real-world data from the first French cohort of patients treated with CAR T-cell therapy
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
EHA 2019 | How will the sequencing of treatments for DLBCL change in the future?
Ulrich Jäger from the Medical University of Vienna, Vienna, AT, discusses how to decide what treatments to use, and when, for patients with relapsed/refractory (R/R)...
EHA 2019 | Access and implementation of CAR T treatment in lymphoma
Marie José Kersten from Amsterdam UMC, Amsterdam, NL, talks about access and implementation of CAR T treatment in lymphoma.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox